Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
BJGP Open|October 4, 2019
White-coat hypertension: management and adherence to guidelines by European and Canadian GPs. A cross-sectional clinical vignette studyXavier Humbert, Sophie Fedrizzi, Emmanuel Touzé, et al.
European Journal of Clinical Pharmacology|January 19, 2026
Clozapine and Mirabegron, a case report of drug-drug interaction with severe consequences in a geriatric patientCamille Guerin, Charlotte Auty, Mélissa Pierre, et al.
Drug Safety - Case Reports|October 18, 2016
High-Dose Verapamil in Episodic and Chronic Cluster Headaches and Cardiac Adverse Events: Is It as Safe as We Think?Joachim Alexandre, Xavier Humbert, Marion Sassier, et al.
Sante Publique (Vandoeuvre-Les-Nancy, France)|August 28, 2018
[Evaluation of a new pharmacovigilance tool: Simplified online reporting for general practitioners]Xavier Humbert, Basile Chrétien, Marion Sassier, et al.
Drug Safety - Case Reports|March 31, 2017
Hazardous Drug Diversion of Valproate from a General Practitioner to his Patient's DogPierre-Marie Morice, Joachim Alexandre, Alexandre Cesbron, et al.
Human Psychopharmacology|November 18, 2020
Could N-acetylcysteine improve the safety of clozapine?Basile Chrétien, Sophie Fedrizzi, Véronique Lelong-Boulouard, et al.
Sante Publique (Vandoeuvre-Les-Nancy, France)|April 5, 2023
General medicine and notification of adverse reactions: contributions of health insurance representativesSophie Fedrizzi, Basile Chrétien, Marion Sassier, et al.
Journal of Hypertension|May 31, 2018
Office white-coat effect tail and long-term cardiovascular risks in the Gubbio residential cohort studyXavier Humbert, Sophie Fedrizzi, Joachim Alexandre, et al.
Therapie|June 14, 2014
[New frequent adverse reaction of PPI in older adults: mild hyponatremia]Laure Peyro Saint Paul, Jocelyne Martin, Marie Buon, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|July 7, 2021
Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database AnalysisCharles Dolladille, Basile Chrétien, Laure Peyro-Saint-Paul, et al.
Pageof 5